Switching from Ropinirole to Rotigotine in Parkinson's Patients
Author Information
Author(s): Kim Han-Joon, Jeon Beom S, Lee Won Yong, Lee Myoung Chong, Kim Jae Woo, Kim Jong-Min, Ahn Tae-Beom, Cho Jinwhan, Chung Sun Ju, Grieger Frank, Whitesides John, Boroojerdi Babak
Primary Institution: Seoul National University Hospital
Hypothesis
Can switching from oral ropinirole to a transdermal rotigotine patch be safely done overnight without loss of efficacy in Korean patients with Parkinson's disease?
Conclusion
The overnight switch from oral ropinirole to the rotigotine patch was well tolerated in Korean patients with no loss of efficacy.
Supporting Evidence
- 85% of subjects completed the 28-day trial period.
- Efficacy results suggested improvements in both motor and nonmotor symptoms.
- 46% of subjects preferred using the patch over oral medications.
Takeaway
Doctors switched patients from one medicine to another overnight, and it worked well without making them feel worse.
Methodology
This was an open-label multicenter trial involving patients with Parkinson's disease who switched from oral ropinirole to a rotigotine patch overnight.
Limitations
The trial was exploratory and not designed to determine the efficacy of rotigotine compared to ropinirole.
Participant Demographics
{"age":"60.0 ± 10.1","gender":{"male":69,"female":47},"duration_of_PD":"5.4 ± 4.0 years"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website